^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Biomarkers of resistance to palbociclib in ER+ primary breast cancer in the PALLET trial

Published date:
11/17/2020
Excerpt:
307 patients were randomized to LET (n=103) or LET+PALBO (n=204) for 14 wks...At the individual gene level, genes significantly associated with non-CCCA after 14wks LET+PALBO included CCNE1, CDK2 and several E2F-related genes (p<0.05)….PALBO resistance was associated with higher baseline expression of cyclin-E1 (both IHC and RNA), CDK2, and genes related to E2F, MYC, interferon and MTOR signalling. These results suggest that multiple identifiable mechanisms of de novo resistance to PALBO are likely to exist in primary ER+ BC.
Secondary therapy:
letrozole
Trial ID: